Cure My Disease

Don't miss your cure!

 Log in / Sign up

New anemia drug may cut iron needs for kidney patients

NCT ID NCT07517744

Disease control Sponsor: Ain Shams University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compared two drugs—roxadustat and darbepoetin alfa—for treating anemia in 35 adults on hemodialysis. The goal was to see if roxadustat improves iron levels and reduces the need for IV iron. Researchers measured changes in iron profile, hemoglobin, and kidney function over 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Roxadustat and darbepoetin alfa
What this could lead to
If successful, this could show that roxadustat improves iron use and reduces the need for IV iron in dialysis patients with anemia.
What could go wrong
This is a small, completed study with only 35 participants, so results may not apply to all patients. It compares two existing drugs, not a new breakthrough.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

35 people

The number who actually took part.

Started

Jun 2024

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Egyptian patients with ESKD- or HD-related anemia who follow up at the Electricity hospital.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * End-stage kidney disease-related anemia * Hemodialysis-related anemia * The mean of the two most recent Hemoglobin values before randomization was 10.5mg/dL or less Exclusion Criteria: * ESA treatment 12 weeks before transfusion * RBC transfusion 8 weeks before transfusion * IV iron transfusion 6 weeks before transfusion * Known history of myelodysplastic syndrome * Known history of multiple myeloma * Known history of hereditary hematologic diseases * Active bleeding or any cause of anemia unrelated to CKD * NYHA Class III or IV congestive heart failure * Liver disease, defined as ALT or AST 3x ULN or greater, or total bilirubin 1.5x ULN or greater * Prior organ transplant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CKD anemia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anemia anemia due to chronic disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CKD anemia CKD anemia in stable dialysis patients

Contacts and locations

Locations

  • Electricity Hospital

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.